ABSTRACT

Observations:

Imiquimod 5% cream, an immune response modifier, licensed for the treatment of external anogenital warts and superficial basal cell carcinomas. Hypopigmentation associated with topical imiquimod use is an infrequent side effect that is attributed to the drug’s Th1 stimulating activity. Herein we report two cases of hypopigmentation which appeared after topical application of imiquimod for genital warts. Dermatologists who are prescribing this drug should be aware of this infrequent side effect associated with topical imiquimod treatment.